Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare CED’s Possible Link With Expedited Drug Approvals Could Arise At MedCAC Review

This article was originally published in The Pink Sheet Daily

Executive Summary

At its next meeting May 16, the Medicare Evidence Development and Coverage Advisory Committee will hear from former CMS and FDA head Mark McClellan, who has supported the notion of linking Medicare’s coverage with evidence development tool with accelerated drug approvals.

You may also be interested in...

Medicare CED Could Enable Expanded Use Of Expedited Drug Approvals, Policy Groups Suggest

Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.

FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO

The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.

US Substitution Rates Lower For Higher Cost Brands

Study sponsored by Association for Accessible Medicines suggests quirks in Part D benefit design and rebating practices are driving the trend.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts